| Literature DB >> 32260272 |
Gabriele Agonigi1, Lucinda K Batchelor2, Eleonora Ferretti3, Silvia Schoch1, Marco Bortoluzzi4, Simona Braccini1, Federica Chiellini1, Lorenzo Biancalana1, Stefano Zacchini5, Guido Pampaloni1, Biprajit Sarkar3, Paul J Dyson2, Fabio Marchetti1.
Abstract
A series ofEntities:
Keywords: bioorganometallic chemistry; diiron complexes; metal-based drugs; selenium; sulphur; vinyliminium ligand
Mesh:
Substances:
Year: 2020 PMID: 32260272 PMCID: PMC7180837 DOI: 10.3390/molecules25071656
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of diiron complexes containing a bridging vinyliminium ligand, 1, obtained by isocyanide (red) / alkyne (blue) coupling.
Scheme 2Synthesis of functionalized mono-, di- and tetrairon complexes via reactions of diiron vinyliminium compounds with elemental sulphur/selenium (E) and PhSSPh. 1a: R = R’ = Me; 1b: R = Xyl, R’ = Ph; 1c: R = Xyl, R’ = CH2OH. 2a: R = R’ = Me, E = Se; 2b: R = Xyl, R’ = Ph, E = S, Y = H; 2c: R = Xyl, R’ = CH2OH, E = S; 2d: R = Xyl, R’ = Ph, E = Se, Y = OMe. 4a: R = R’ = Me, E = Se; 4b: R = Xyl, R’ = Ph, E = S; 4c: R = Xyl, R’ = CH2OH, E = S; 4d: R = Xyl, R’ = Ph, E = Se. 5a: R = R’ = Me, E = Se; 5b: R = Xyl, R’ = Ph, E = S. Xyl = 2,6-C6H3Me2.
Figure 1DFT-optimized structure of 2b, Z isomer (C-PCM/ωB97X/def2-SVP calculation, chloroform as continuous medium). Hydrogen atoms are omitted for clarity. Selected computed bond lengths (Å): Fe(1)-Fe(2) 2.534; Fe(1)-C(μCO) 1.909; Fe(2)-C(μCO) 1.902; Fe(1)-C(3) 2.033; Fe(2)-C(3) 1.977; Fe(2)-C(2) 2.143; Fe(1)-C(1) 1.878; Fe(2)-C(CO) 1.769; Fe(1)-Cp(average) 2.082; Fe(2)-Cp(average) 2.105; C(3)-C(2) 1.424; C(2)-C(1) 1.437; C(2)-S 1.732; C(1)-N 1.299. Selected computed angles (°): Fe(1)-C(3)-C(2) 74.3; Fe(2)-C(3)-C(2) 123.2; C(1)-C(2)-C(3) 111.9; C(3)-C(2)-S 128.5; S-C(2)-C(1) 117.2; C(2)-C(1)-N 132.0. Selected Mulliken charges (a.u.) in parenthesis. Inset 1: Gibbs energy different between E and Z isomers of 2b (EDF2/6-31G** calculations). Cartesian coordinates of the EDF2 geometries are collected in the SI. Inset 2: HOMO of 2b (surface isovalue = 0.05 a.u.).
Figure 2DFT-optimized structure of 2d, Z isomer (C-PCM/ωB97X/def2-SVP calculation, chloroform as continuous medium). Hydrogen atoms are omitted for clarity. Selected computed bond lengths (Å): Fe(1)-Fe(2) 2.536; Fe(1)-C(μCO) 1.920; Fe(2)-C(μCO) 1.895; Fe(1)-C(3) 2.038; Fe(2)-C(3) 1.976; Fe(2)-C(2) 2.119; Fe(1)-C(1) 1.876; Fe(2)-C(CO) 1.770; Fe(1)-Cp(average) 2.082; Fe(2)-Cp(average) 2.104; C(3)-C(2) 1.419; C(2)-C(1) 1.430; C(2)-Se 1.896; C(1)-N 1.299. Selected computed angles (°): Fe(1)-C(3)-C(2) 73.1; Fe(2)-C(3)-C(2) 123.4; C(1)-C(2)-C(3) 113.0; C(3)-C(2)-Se 128.2; Se-C(2)-C(1) 116.7; C(2)-C(1)-N 133.0. Selected Mulliken charges (a.u.) in parenthesis. Inset1: Gibbs energy different between E and Z isomers of 2d (EDF2/6-31G** calculations). Cartesian coordinates of the EDF2 geometries are collected in the SI. Inset2: HOMO of 2d (surface isovalue = 0.05 a.u.).
Figure 3Molecular structure of [FeCp(CO){SeC1(NMe2)C2HC3(Me)}], 3. Displacement ellipsoids are at the 30% probability level.
Selected bond lengths (Å) and angles (°) for 3.
| Molecule 1 | Molecule 2 | |
|---|---|---|
| Fe(1)-Se(1) | 2.391(8) | 2.357(9) |
| Fe(1)-Cp | 2.07(5)–2.17(5) | 2.09(5)–2.10(5) |
| Fe(1)-C(4) | 1.74(4) | 1.83(4) |
| Fe(1)-C(3) | 1.96(4) | 1.92(5) |
| C(4)-O(1) | 1.12(6) | 1.09(5) |
| Se(1)-C(1) | 1.90(4) | 1.88(5) |
| C(1)-C(2) | 1.46(6) | 1.43(6) |
| C(2)-C(3) | 1.39(6) | 1.39(6) |
| C(3)-C(5) | 1.50(6) | 1.43(7) |
| C(1)-N(1) | 1.28(6) | 1.27(6) |
| N(1)-C(6) | 1.53(6) | 1.50(6) |
| N(1)-C(7) | 1.52(5) | 1.52(6) |
| Se(1)-Fe(1)-C(3) | 84.9(13) | 86.6(14) |
| Fe(1)-C(4)-O(1) | 178(4) | 171(4) |
| Fe(1)-Se(1)-C(1) | 96.5(13) | 98.3(14) |
| Se(1)-C(1)-C(2) | 115(3) | 108(3) |
| C(1)-C(2)-C(3) | 118(4) | 127(4) |
| C(2)-C(3)-Fe(1) | 126(3) | 119(4) |
| Sum at N(1) | 360(6) | 360(6) |
| Sum at C(1) | 360(6) | 359(6) |
| Sum at C(3) | 360(6) | 360(6) |
Overview of the main oxidation and reduction potentials (V vs. Fc+/Fc) at a scan rate of 100 mV/s determined by cyclic voltammetry in MeCN for selected iron complexes. The peak-to-peak separation (ΔEp) is determined by the difference between two peak potentials for a given redox couple. aEpa for an irreversible process.
| Compound | Oxidation [V] | Reduction [V] | ΔEp (red) [mV] |
|---|---|---|---|
|
| +0.65 a | −1.37 | 108 |
|
| +0.73 a | −1.35 a | - |
|
| +0.12 a | −1.7 a | - |
|
| - | −0.78 a | - |
|
| −0.44 a ÷ +0.66 a | −1.29 | 87 |
IC50 values (μM) determined for compounds 3, 4a–d (and their vinyliminium precursors 1a–c), 5a–b, 6, cisplatin and RAPTA-C on human ovarian carcinoma (A2780), human ovarian carcinoma cisplatin resistant (A2780CisR) and human embryonic kidney (HEK-293) cell lines after 72 h exposure. Values are given as the mean ± SD. a See reference [39].
| Compnd. | A2780 | A2780cisR | HEK-293 |
|---|---|---|---|
|
| 35 ± 3 | 86 ± 7 | >200 |
|
| 0.50 ± 0.06 | 1.2 ± 0.2 | 2.4 ± 0.2 |
|
| 11.6 ± 0.6 | 21.2 ± 1.6 | 13.4 ± 1.0 |
|
| 16.1 ± 1.3 | 20 ± 2 | 19 ± 2 |
|
| >200 | >200 | >200 |
|
| 0.6 ± 0.1 | 1.2 ± 0.6 | 0.72 ± 0.04 |
|
| 5.7 ± 0.8 | 12.8 ± 0.7 | 9.1 ± 0.7 |
|
| 1.4 ± 0.2 | 2.8 ± 0.3 | 2.2 ± 0.6 |
|
| 15.6 ± 0.8 | 28 ± 2 | 26 ± 3 |
|
| 0.5 ± 0.2 | 1.4 ± 0.2 | 0.7 ± 0.1 |
|
| 3.7 ± 0.4 | 14 ± 2 | 6.7 ± 0.6 |
| cisplatin | 2.7 ± 0.1 | 26 ± 3 | 10.0 ± 0.7 |
| RAPTA-C | >200 | >200 | >200 |
Figure 4Fluorescence kinetics measurements of intracellular reactive oxygen species (ROS). A2780 cells incubated for 24 h with 10 µM of iron compounds at 37 °C.
Turnover numbers (TON) of iron compounds (10 μM) in the aerobic oxidation of NADH (220 μM) in a 5% DMSO phosphate buffered solution at 37 °C after 25 h. FeSO4 used as a reference compound.
| Compound | TON |
|
| 3.8 |
|
| 4.1 |
|
| 3.7 |
|
| 1.8 |
|
| 1.6 |
|
| 3.7 |
|
| 3.5 |
| FeSO4 [a] | 2.3 |
[a] NADH oxidation over time not significantly different from the blank experiment.
Chart 4Structure of the cation of 4a.
Crystal data and measurement details for 3.
| 3 | |
|---|---|
| Formula | C12H15FeNOSe |
| FW | 324.06 |
| T, K | 100(2) |
| 0.71073 | |
| Crystal system | Monoclinic |
| Space group | |
| 13.454(3) | |
| 7.675(2) | |
| 12.285(2) | |
| 99.07(3) | |
| Cell Volume, Å3 | 1252.5(5) |
| Z | 4 |
| 1.719 | |
| μ, mm−1 | 4.088 |
| F(000) | 648 |
| Crystal size, mm | 0.21 × 0.19 × 0.15 |
| θ limits,° | 1.533–24.999 |
| Reflections collected | 11149 |
| Independent reflections | 2119 [ |
| Data/restraints/parameters | 2119/350/290 |
| Goodness on fit on F2 | 1.116 |
| 0.1175 | |
| 0.2914 | |
| Largest diff. peak and hole, e Å−3 | 1.622/–1.857 |
Overview of stability of compounds in aqueous media.
| Comp. | Stability in DMSO- | Stability in DMSO/RPMI-1640 ( |
|---|---|---|
|
| <15% degradation (3:2) | |
|
| ca. 50% degradation (1:1) | |
|
| <15% degradation (2:1) | |
|
| <15% degradation (1:1) | |
|
| ||
|
|
a After 24 h at 37 °C (1H NMR), [NaCl] ≈ 0.05 M. b Compounds detected (IR) in CH2Cl2 phase after 72 h at 37 °C. c Bands at 2097m, 1990m-s (4a), 1954m-sh, 1895w, 1814m (4a), 1670w-sh (4a), 1631s cm−1.